@article{676a30d7eecc440c9e359fa015d46e40,
title = "Reply to Drs Munkholm and Paludan-M{\"u}ller{\textquoteright}s comment on our paper “Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial”",
author = "Nettis, {Maria A.} and Pariante, {Carmine M.} and Valeria Mondelli",
note = "Funding Information: This research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. VM is supported by MQ: Transforming Mental Health (Grant: MQBF1) and by the Medical Research Foundation (grant number MRF-160-0005-ELP-MONDE). Funding Information: MAN declares no conflict of interest. CMP and VM have received research funding from Johnson & Johnson as part of a research programme on depression and inflammation. CMP has received research funding from the Medical Research Council (UK) and the Wellcome Trust for research on depression and inflammation as part of two large consortia that also include Johnson & Johnson, GSK and Lundbeck.",
year = "2021",
month = aug,
doi = "10.1038/s41386-021-01042-1",
language = "English",
volume = "46",
pages = "1552--1553",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Springer Nature [academic journals on nature.com]",
number = "9",
}
